FUJI YAKUHIN CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1930-02-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.fujiyakuhin.co.jp
Study of FFI-1010 in Pediatric Kidney Disease
Phase 3
Completed
- Conditions
- Children Under 18 Years Old With Kidney Disease
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03345316
- Locations
- 🇯🇵
Fuji Yakuhin Investigational sites, Tokyo, Japan
Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
Phase 3
Completed
- Conditions
- Hyperuricemia With or Without Gout
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 201
- Registration Number
- NCT03100318
- Locations
- 🇯🇵
Tokyo, Tokyo, Japan
Study of FYU-981 in Hyperuricemia With or Without Gout
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT03006445
Mass Balance Study of FYU-981
Phase 2
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- Drug: 14C-FYU-981
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT02901366
Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02837198
Clinical Pharmacology of FYU-981 (Effect on QT/QTc Interval)
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02515864
Study of FYU-981 in Hyperuricemia With or Without Gout
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2017-02-14
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT02416167
- Locations
- 🇯🇵
Japan, Tokyo and Other Japanese City, Japan
Repeated Dose Phase I Study of FYU-981
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: FYU-981, (Oral daily dosing for 7 days)Drug: Placebo, (Oral daily dosing for 7 days)
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2015-01-28
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT02348333
- Locations
- 🇯🇵
Japan, Tokyo, Japan
Single Dose Phase I Study of FYU-981
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Placebo, (Oral single dosing)Drug: FYU-981, (Oral single dosing)
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2015-01-28
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT02348307
- Locations
- 🇯🇵
Japan, Tokyo, Japan
Clinical Pharmacology of FYU-981 (Subjects With Renal Insufficiency)
Phase 1
Completed
- Conditions
- HealthyRenal Insufficiency
- Interventions
- Drug: FYU-981, (Oral single dosing)
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT02347046
- Locations
- 🇯🇵
Japan, Kagoshima, Japan
© Copyright 2025. All Rights Reserved by MedPath